My laboratory focuses on the molecular mechanisms of differentiation and transformation of hematopoietic stem cells and progenitors. Specifically, we study the initiation and progression of both lymphoid (T-ALL) and myeloid (AML, CML, CMML) leukemias.
Our work has identified and studied a number of novel oncogene proteins (including NOTCH1), tumor suppressor proteins (including FBXW7, TET2, CYLD, EZH2, UTX, cohesins), and downstream oncogenic signaling pathways. We have used these pathways to design molecularly targeted therapeutic protocols that inhibit the induction of or affect the maintenance of the disease. Our laboratory also studies the mechanisms of hematopoietic stem cell differentiation and self-renewal using both genomic and genetic approaches.
We currently have several areas of focus in our lab:
- the impact of DNA methylation on stem cell transformation
- the mapping of long noncoding RNAs in a number of human tumors
- the impact of three-dimensional chromosomal architecture in cancer
- the role of stress responses in human malignancy
- the in vivo mapping of the tumor microenvironment for acute leukemia
We have recently expanded our scope to include the regulation of tumor progression and metastasis in selected solid tumors, with an emphasis on cancer-initiation mechanisms, including protein stability, epigenetics, and the tumor microenvironment.
Professor, Department of Pathology
Chair, Department of Pathology
PhD from Universite de Paris III.
Cell. 2017 Aug 17; 170(6):1079-1095.e20
AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS [Meeting Abstract]
Haematologica (Roma). 2017 JUN 26; 102:92-92
BMC genomics. 2017 Jun 05; 18(1):434-434
Nature immunology. 2017 May 18; 18(6):595-597
Nature communications. 2017 Apr 25; 8:15102-15102
Cancer discovery. 2017 Feb 23; 7(5):506-521
Journal of experimental medicine. 2017 Feb 11; 214(3):773-791